Abstract 1402
Background
Neoadjuvant chemotherapy is promising to improve the survival of locally advanced gastric cancer. However, optimal regimen and duration of treatment have not been established. We previously reported the primary results of COMPASS-D trial (ASCO-GI 2019). Herein, we report the results of subgroup analyses of efficacy by baseline disease characteristics and demographics.
Methods
Patients with M0 and either T4 or T3 in case of junctional cancer or schirrhous type received 2 or 4 courses of cisplatin (60 mg/m2 at day 8) / S-1 (80 mg/m2 for 21 days with 1 week rest) or docetaxel (40 mg/m2 at day 1) / cisplatin (60 mg/m2 at day 1) / S-1 (80 mg/m2 for 14 days with 2 weeks rest) as neoadjuvant chemotherapy. Then, patients underwent D2 gastrectomy and adjuvant S-1 chemotherapy for 1 year. The primary endpoint was 3-year overall survival. Subgroup analysis was performed in each regimen (CS vs DCS) and duration (2 vs 4 courses), stratified by age, gender, esophageal invasion, macroscopic type, histological type, cT, and cN.
Results
Between Oct 2011 and Sep 2014, 132 patients were assigned to CS (n = 66; 33 in 2-courses and 33 in 4-courses) and DCS (n = 66; 33 in 2-courses and 33 in 4-courses). The 3-year OS was 58.1% in 2-courses CS, 58.1% in 4-courses CS, 48.5% in 2-courses DCS, and 71.9% in 4-courses DCS. Subgroup analyses were summarized in the table.Table:
778P
Subgroup | HR of 4-sourses (95%CI) | HR of DCS (95%CI) |
---|---|---|
Overall | 0.77 (0.43-1.22) | 0.80 (0.48-1.34) |
Age < 70 y.o. | 0.82 (0.45-1.52) | 0.88 (0.48-1.62) |
Age = > 70 y.o. | 0.49 (0.17-1.39) | 0.68 (0.26-1.76) |
Male | 0.53 (0.27-1.05) | 0.81 (0.42-1.54) |
Female | 1.22 (0.51-2.90) | 0.79 (0.33-1.87) |
Esophageal invasion- | 0.72 (0.40-1.31) | 0.71 (0.39-1.27) |
Esophageal invasion+ | 0.73 (0.24-2.17) | 1.06 (0.36-3.16) |
Schirrhous or large Type3 | 0.47 (0.22-1.00) | 0.82 (0.41-1.63) |
Non schirrous or large Type3 | 0.74 (0.23-2.41) | 0.50 (0.13-1.87) |
Differentiated | 0.37 (0.08-1.66) | 0.38 (0.09-1.71) |
Undiffirentiated | 0.66 (0.32-1.36) | 1.24 (0.63-2.43) |
cT3 or T4a | 0.66 (0.38-1.17) | 0.76 (0.44-1.32) |
cT4b | N/A | 2.33 (0.26-21.4) |
cN0 | 0.77 (0.32-1.86) | 0.74 (0.31-1.80) |
cN + | 0.66 (0.34-1.27) | 0.87 (0.46-1.66) |
Conclusions
The DCS regimen and duration 4-courses showed a beneficial tendency as a neoadjuvant setting regardless of disease characteristics and demographics. The 4-courses DCS is widely applicable to future phase III study to confirm of neoadjuvant chemotherapy for locally advanced gastric cancer.
Clinical trial identification
UMIN000006378.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Nongovermental Organization, Kanagawa Standard Anti-cancer Therapy Support System.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3330 - Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Presenter: Leonora De Boo
Session: Poster Display session 2
Resources:
Abstract
3971 - Unravelling the biological characteristics of MammaPrint extreme risk subgroups
Presenter: Rajith Bhaskaran
Session: Poster Display session 2
Resources:
Abstract
5871 - Residual Cancer burden as a prognostic factor in a large series of Neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes
Presenter: Catalina Falo
Session: Poster Display session 2
Resources:
Abstract
5014 - Clinical validation of CanAssist Breast in a Spanish cohort
Presenter: Manjiri Bakre
Session: Poster Display session 2
Resources:
Abstract
2787 - Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer
Presenter: Peter A. Fasching
Session: Poster Display session 2
Resources:
Abstract
4301 - Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Presenter: Gaia Griguolo
Session: Poster Display session 2
Resources:
Abstract
3205 - Frequency of germline mutations in women's cancer susceptibility genes in a large cohort of Chinese breast cancer patients
Presenter: Ning Liao
Session: Poster Display session 2
Resources:
Abstract
4091 - Triple blinded Prospective Study assessing the Impact of Genomics & Artificial Intelligence Watson For Oncology (WFO) on MDT’s Decision of Adjuvant Systemic Therapy for Hormone Receptor Positive Early Breast Carcinoma-
Presenter: Somashekhar Sampige Prasannakumar
Session: Poster Display session 2
Resources:
Abstract
4359 - Prognostic significance of Progesterone Receptor levels in luminal-like Her2- early Breast Cancer patients. A retrospective single Cancer Center analysis.
Presenter: Anna Diana
Session: Poster Display session 2
Resources:
Abstract
1369 - PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis
Presenter: Francesco Schettini
Session: Poster Display session 2
Resources:
Abstract